Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption
Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption
Acetazolamide improves central sleep apnea related to opium consumption.
This is a double-blind, placebo-controlled, cross-over designed study to evaluate the effect
 of acetazolamide on central apneas in opium-user patients.

 We are going to invite 12 eligible patients to enter our study. this sample will be obtained
 from the referral patients to Masih Daneshvari hospital sleep Lab. Eligible patients will
 undergo a full night polysomnography (PSG) to have a new measure of apnea indexes as
 baseline. Epwoth Sleepiness Scale Questionnaire (ESS) will be filled by the patient the night
 of the study.also an arterial blood sample will be obtained at the morning of each study. if
 the patient have more than 5 central apneas in each hour he/she will be scheduled to randomly
 receive a box containing 6 capsules to use one hour before bedtime at coming nights. The
 prescriber physician who will also score the tests and the patients are unaware either these
 capsules are acetazolamide 250mg or placebo. at 6th night we will perform PSG together with
 ESS questionnaire and arterial blood gas (ABG). after 2 weeks washout the patient receive
 another box containing 6 capsules with similar appearance to previous ones. If the patient
 receives acetazolamide in the first six nights, he/she will receive placebo in the second
 phase of the study and if the patient receives placebo in the first phase, he/she will
 receive acetazolamide in the second phase.

 after the second 6 days, the third PSG will be performed plus ESS measurement and morning ABG
 sampling. Coded polysomnograms will be scored blindly.
Inclusion Criteria:

 -  Opium or opioid use for at least two months in a daily manner

 -  Presence of five or more central sleep apnea per hour in a full-night recorded PSG

 Exclusion Criteria:

 -  Congestive heart failure

 -  living in high altitude

 -  Chronic Obstructive Pulmonary Disease (COPD)

 -  Carbon dioxide partial pressure (pCO2) elevation due to other respiratory diseases

 -  Body Mass Index (BMI) > 32

 -  Obesity Hypoventilation Syndrome

 -  Severe renal or liver disorders

 -  Using Benzodiazepine

 -  Using Theophylline